View speaker details

Kent Kedl is a Partner in Control Risks, Greater China and North Asia. He is responsible for Control Risks’ practices across mainland China, Hong Kong, Macau, Taiwan, the Koreas and Mongolia. He has worked in Asia since the early 1980s.

Kent has consulted with multi-national and Asian corporations on a range of risk and strategy issues, such as M&A and organic growth strategy, crisis management and operational business controls, and strategic and organisational development programs. Kent has particular expertise in the Asia-Pacific healthcare, food and beverage, and consumer products sectors.

Formerly, Kent was responsible for the Compliance, Forensics and Intelligence practice throughout Asia-Pacific. Prior to joining Control Risks, Kent was general manager and co-owner of Technomic Asia, a market strategy consulting firm.

View speaker details

Francis was appointed Vice President, Atlas Copco (China) Investment Co., Ltd. in August, 2016. Based in Shanghai, he oversees Atlas Copco’s operations in Greater China and Mongolia, with more than 35 legal entities.
Over the past 23 years, he has held various managerial positions with increased responsibility within Atlas Copco Group and has been working most of his time in different countries in Europe and Asia. Prior to his current position, he was the General Manager of Atlas Copco Singapore & Malaysia.
Francis is a Belgian citizen, and holds a Master’s degree in Business Administration.

View speaker details

E. Allan Gabor is president of Merck China, and managing director of Merck Performance Materials China. He is also a permanent member of Merck’s Performance Materials Leadership Team, responsible for China. As president of Merck China, he is responsible for developing and driving growth strategies in this key country and building on the company’s 350-year presence and reputation. China is considered one of the Group’s strategic countries, with all three business sectors of Merck developing rapidly in the market.

Prior to this role, he was the president of Asia Pacific for Biopharma, Merck Group from 2016 to 2018. Before 2016, he was the president and chief executive officer for Merck’s Biopharma business in China, and was instrumental in expanding Merck’s Asian footprint. This was achieved through a series of investments, including establishing Merck’s new EUR170 million world-class pharmaceutical manufacturing facility in Nantong, Jiangsu Province, as well as building an extensive network with leading academic and medical institutions for collaborations.

Before joining Merck, Mr Gabor spent 25 years at Pfizer in leadership roles including chair and general manager for China, and regional president for North Asia, Russia, India, Turkey and Eastern Europe. Mr Gabor successfully launched many of Pfizer's innovative medicines in China, and opened the China Regional Investment Centre and a state-of-the-art research and development centre in Shanghai.

In recognition of his tireless contribution towards the economic construction, social development and international exchange and cooperation of Shanghai, Mr Gabor has been awarded the Magnolia (Baiyulan) Award twice by the Shanghai Municipal Government.

Mr Gabor holds a BA in Communications from the College of Wooster and pursued further education at the University of Tennessee and Harvard Business School.